This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

EnteroMedics: Fat Zapper or Pulsing Placebo?

ST. PAUL, Minn. (TheStreet) --Into the obesity treatment fray rumbles EnteroMedics (ETRM), which is developing a surgically implanted device that uses electrical pulses to block the primary nerve regulating digestion. Unlike pacemakers, patients power the EnteroMedics' VBLOC device on and off with a control belt worn around the waist. When VBLOC is on, patients are supposed to feel less hungry, eat less and lose weight.

VBLOC is an obesity treatment potentially less invasive and reversible, unlike gastric bypass surgery. But EnteroMedics is also developing VBLOC at a time when the obese have far easier treatment options in the recently approved pills from Vivus (VVUS) and Arena Pharmaceuticals (ARNA).

EnteroMedics is currently conducting a phase III study of VBLOC compared to a dummy device in obese patients. Results from the study are expected before the end of February.

With a stock price under $3 per share and a market cap of $122 million, the upside potential in EnteroMedics heading into the phase III study data is greater than the downside risk. But, of course, EnteroMedics is "cheap" today because of significant doubts about the efficacy of VBLOC. A previous phase III study failed badly.

In its favor, EnteroMedics designed the current phase III study to optimize the weight loss potential of VBLOC while at the same time make it more difficult for control patients to also lose weight. For this reason, EnteroMedics has better odds of winning with the current VBLOC study than it did the last time.

On balance, however, it's tough to be overly optimistic about VBLOC's chances. Data from the previous study raise many red flags. Let's take a look.

The EMPOWER study enrolled 294 obese patients with a mean Body Mass Index (BMI) of 41. [A 5' 4" woman with a BMI of 41 would weigh 240 pounds.]

All the patients underwent surgical implantation of the VBLOC device. Two-thirds of the patients were randomized into the treatment group, which meant their VBLOC devices were fully operational. The remaining one third of patients were randomized to the control group, with VBLOC devices that were set at a minimal, sub-therapeutic level. Patients in both arms also underwent weight-loss counseling.

Stock quotes in this article: ETRM, ARNA, VVUS 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs